TrialPloS one2017

A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma.

Stina Wichert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.